A clinical phase I/II assay evaluated a peptide-based vaccine that contained peptides derived from the TAA: MUC1 (SAPDNRPAL), CEA (YLSGADLNL), and ErbB2 (KIFGSLAFL) in patients with ovarian and breast cancer. Here, ERBB2 is linked to breast cancer.